
BMY's 4.4% Dividend Masks Looming Patent Cliff Risks
Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.
BMYCELGrhealthcaredividend sustainability










Investing.com··Timothy Fries